Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Fineline Cube Jan 20, 2026
Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Fineline Cube Jan 19, 2026
Company

RemeGen’s Q1 2024 Revenues Surge 96.41% YOY, R&D Spending Outpaces Income

Fineline Cube Apr 29, 2024

China-based pharmaceutical company RemeGen (HKG: 9995) has reported its financial results for the first quarter...

Company

Astellas Pharma Inc. Reports Revenue Growth in FY2023, Driven by Xtandi and Padcev Sales

Fineline Cube Apr 29, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the year ended...

Company Drug

iRegene’s Pioneering Cell Therapy NouvNeu001 Administered in Wuhan for Parkinson’s Disease

Fineline Cube Apr 29, 2024

Wuhan-based cell therapy developer iRegene has reached a clinical milestone with the administration of its...

Company Deals

Kexing Pharmaceutical Secures Global Rights for Qingfeng’s Generic Olaparib

Fineline Cube Apr 29, 2024

China’s Kexing Pharmaceutical (SHA: 688136) has secured a global commercialization licensing agreement with Qingfeng Pharmaceutical...

Company Drug

Chengdu Kanghong Pharmaceutical Gets US FDA Nod for Clinical Trial of KH658 for Wet AMD

Fineline Cube Apr 29, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a leading pharmaceutical company based in China,...

Company Drug

CARsgen Therapeutics Submits CAPA Report to US FDA Following Clinical Hold

Fineline Cube Apr 29, 2024

CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...

Company Drug

Yantai Dongcheng Pharmaceutical Receives NMPA Approval for Advanced Solid Tumor Therapy

Fineline Cube Apr 29, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...

Company Drug

Keymed Biosciences’ Stapokibart Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Study

Fineline Cube Apr 29, 2024

China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that its IL-4Rα monoclonal antibody...

Company Deals

Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China

Fineline Cube Apr 28, 2024

Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering...

Company Drug

Pfizer’s Gene Therapy Beqvez Wins FDA Nod for Moderate-to-Severe Hemophilia B

Fineline Cube Apr 28, 2024

The US Food and Drug Administration (FDA) has granted marketing authorization to Pfizer (NYSE: PFE)...

Company Drug

Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval

Fineline Cube Apr 28, 2024

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...

Company Drug

HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe

Fineline Cube Apr 28, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...

Policy / Regulatory

China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement

Fineline Cube Apr 28, 2024

The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...

Company Drug

Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment

Fineline Cube Apr 28, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...

Company Medical Device

Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 28, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023,...

Company

United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships

Fineline Cube Apr 28, 2024

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year...

Company Drug

AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial

Fineline Cube Apr 28, 2024

AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...

Company Policy / Regulatory

Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations

Fineline Cube Apr 28, 2024

Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...

Company Deals

Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation

Fineline Cube Apr 28, 2024

China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China...

Company Deals

AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China

Fineline Cube Apr 28, 2024

Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received...

Posts pagination

1 … 313 314 315 … 611

Recent updates

  • AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
  • Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease
  • Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data
  • Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise
  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.